Resources

Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme.

A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.

Microbiotica announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.

The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.

Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).

AAVantgarde Bio, a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1.

EnteroBiotix Limited announced positive final results from for EBX-102-02, a therapeutic for irritable bowel syndrome with constipation and diarrhoea.

In this blog, Blood Cancer UK reflects on a year of partnership with BIA — from raising vital funds and forging new connections in life sciences, to amplifying the voice of people affected by blood cancer across the UK.

Our final blog of 2025 celebrates some excellent fundraising news to close the year, while highlighting key opportunities to engage with and shape the UK life sciences agenda — including the development of UK engineering biology, data policy, a cross-cancer research policy position and salary benchmarking.

NRG Therapeutics, an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).

Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.

BIA’s influence and connect were out in force last week – grasping a timely opportunity to get our key Autumn Budget asks across impactfully to the Chancellor with the clear backing of over 200 member CEOs, and putting on a dynamic, pro-innovation Future of UK Regulation conference, featuring MHRA and NICE CEOs amongst other key stakeholders.

Clinical trial results on drug free obesity treatment, published in peer reviewed journal, Obesity. Commercial launch in UK first, planned for 2027.

Arecor Therapeutics announces that it has concluded a positive Type C meeting with the US FDA for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.

AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open in the UK.

Microbiotica has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at Digestive Disease Week (DDW) 3rd – 6th May in San Diego.

Alchemab Therapeutics (Alchemab) today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.

In a world of uncertainty, Britain’s biotech future looks strong.

Mosaic Therapeutics, Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies, announced the in-licensing of two clinical-stage oncology programs.